Sirolimus (Rapamycin) 53123-88-9 — China API Manufacturer | USP/EP/JP R&D to Production

China Manufacturing Landscape for Sirolimus (Rapamycin)

Sirolimus, also known as Rapamycin (CAS 53123-88-9), is a macrocyclic lactone immunosuppressant originally isolated from Streptomyces hygroscopicus, now widely used in organ transplant rejection prophylaxis, drug-eluting coronary stents, and emerging oncology and rare disease applications. China has developed world-class fermentation infrastructure for macrolide compound production, positioning domestic manufacturers as primary global suppliers of Sirolimus API. Our production facility operates dedicated Sirolimus fermentation and purification lines with annual capacity serving major generic pharmaceutical manufacturers across Asia, Europe, and the Americas.

The Chinese manufacturing advantage for Sirolimus stems from decades of investment in industrial fermentation technology, originally developed for the antibiotics sector and subsequently refined for high-value immunosuppressant production. Deep expertise in strain improvement through classical mutagenesis and rational metabolic engineering, combined with large-scale fermentation infrastructure and downstream purification capabilities, enables Chinese manufacturers to deliver consistently high-quality Sirolimus at cost points that reflect genuine production efficiencies rather than compromised quality.

Manufacturing Process & Facility

Sirolimus production begins with seed culture preparation from a qualified working cell bank of a high-yielding Streptomyces hygroscopicus production strain, progressing through a multi-stage inoculum expansion program before transfer to production-scale fermenters (10,000-60,000 liters). Fermentation parameters including dissolved oxygen, temperature profile, carbon and nitrogen source feeding strategies, and pH control are managed by advanced distributed control systems (DCS) with automated data logging. Typical fermentation cycles run 7-10 days, with real-time titer monitoring by HPLC to determine optimal harvest timing.

Post-fermentation extraction employs organic solvent extraction of the broth, followed by multi-step chromatographic purification including macroporous resin adsorption, silica gel column chromatography, and preparative HPLC to achieve pharmacopeial-grade purity. Final crystallization under controlled anti-solvent conditions yields the required crystal form. The facility is equipped with dedicated biowaste treatment systems, solvent recovery units, and operates under strict biosafety and environmental compliance standards. Current annual production capacity is 300 kg of Sirolimus API.

Quality Standards & Multi-Pharmacopeial Compliance

Our Sirolimus API is manufactured to comply with USP, EP, and JP pharmacopeial monograph requirements simultaneously. HPLC purity consistently exceeds 98.0%, with critical related substances including 41-O-demethylsirolimus and ring-opened sirolimus controlled well below specified limits. Identity is confirmed by IR, UV-Vis spectroscopy, and HPLC retention time comparison against qualified reference standards. Specific optical rotation is tested to confirm stereochemical integrity of the complex macrocyclic structure.

Extended analytical characterization includes residual solvent profiling by GC-HS, elemental impurity analysis by ICP-MS per ICH Q3D, water content by Karl Fischer, microbial enumeration and endotoxin testing, and particle size analysis. Stability programs conducted under ICH Q1A conditions (long-term at 2-8°C and accelerated at 25°C/60% RH) support a validated retest period of 24 months under recommended cold storage conditions.

Regulatory Documentation

We maintain active Drug Master Files with the US FDA (Type II DMF) and provide EU ASMF documentation for European marketing authorization submissions. Full CTD Module 3.2.S documentation packages include manufacturing process description with critical process parameters, control strategy rationale, impurity qualification data, analytical method validation reports, and complete stability data. Additional regulatory support includes quality certificates from NMPA and international inspection reports, TSE/BSE statements, environmental impact assessments, and starting material qualification documentation for the fermentation strain and key raw materials.

Packaging & Logistics

Sirolimus API is packaged in light-protective amber glass bottles or double PE bags within sealed aluminum containers, in quantities of 100 g, 500 g, 1 kg, and 5 kg per unit. Cold chain integrity is critical for this temperature-sensitive API; all shipments are dispatched via validated cold chain logistics (2-8°C) with continuous temperature monitoring and data logger records provided with each shipment. International delivery via cold chain air freight from Shanghai typically reaches destinations within 5-10 business days, with pre-arranged customs documentation to minimize clearance delays for controlled-temperature shipments.

Competitive Pricing & Supply Reliability

Direct manufacturer pricing for Sirolimus reflects the capital-intensive nature of fermentation-based production while remaining highly competitive against alternative sources. Our pricing structure rewards volume commitment with graduated discounts for annual purchase agreements exceeding 50 kg. Production planning operates on a quarterly campaign basis with standard lead times of 6-10 weeks for confirmed orders. For customers with critical supply requirements, we offer dedicated batch reservation programs and safety stock arrangements at our warehouse facility, ensuring product availability regardless of production scheduling constraints.

Sirolimus (Rapamycin) Specifications